Business Context and Reporting Period
Company: Aspen Aerogels, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2020
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics related to the offering include:
- Shares Offered: 1,700,000 shares of common stock.
- Offering Price: $8.25 per share.
- Gross Proceeds: Approximately $14.0 million (before underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 255,000 additional shares.
- Expected Closing Date: On or about February 18, 2020.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. These operational metrics are not included in this specific 8-K report.
Material Changes
The primary material change is the execution of an underwriting agreement with Craig-Hallum Capital Group LLC to raise capital. This represents a significant increase in the company's equity capital pending the closing of the transaction.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release announcing the pricing of the offering. The proceeds are intended to be used as described in the related prospectus supplement, though specific allocation details are not enumerated in this text.
Risks and Contingencies:
- The offering is subject to customary closing conditions.
- Forward-looking statements regarding the completion of the offering and use of proceeds are subject to risks and uncertainties.
- Actual results may differ materially due to market conditions and other factors detailed in the company's Form 10-K and Form 10-Q filings.
Investor Verification Checklist
- Verify the final closing date of the offering (anticipated February 18, 2020).
- Confirm the final net proceeds after deducting underwriting discounts and offering expenses.
- Check if the underwriters exercised the option to purchase the additional 255,000 shares.
- Review the final prospectus supplement for the specific intended use of proceeds.
- Examine the most recent Form 10-Q or 10-K for current liquidity and debt positions not covered in this 8-K.